Novo Nordisk A/S rose the most in a month after its diabetes blockbuster Ozempic beat Eli Lilly & Co.’s older drug Trulicity in a real-world survey of certain US patients.
www.bloomberg.com
#Novo #Rises #Ozempic #Beats #Older #Lilly #Drug #Survey
Novo Rises After Ozempic Beats Older Lilly Drug in Survey
